These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://haseebgznv664854.mybloglicious.com/59010376/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide